| Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV α-synucleinopathy CY Chung, JB Koprich, H Siddiqi, O Isacson Journal of Neuroscience 29 (11), 3365-3373, 2009 | 465 | 2009 |
| The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease P Huot, TH Johnston, JB Koprich, SH Fox, JM Brotchie Pharmacological reviews 65 (1), 171-222, 2013 | 384 | 2013 |
| Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease JB Koprich, C Reske-Nielsen, P Mithal, O Isacson Journal of neuroinflammation 5, 1-12, 2008 | 381 | 2008 |
| Animal models of α-synucleinopathy for Parkinson disease drug development JB Koprich, LV Kalia, JM Brotchie Nature Reviews Neuroscience 18 (9), 515-529, 2017 | 243 | 2017 |
| α-Synuclein-based animal models of Parkinson's disease: challenges and opportunities in a new era NP Visanji, JM Brotchie, LV Kalia, JB Koprich, A Tandon, JC Watts, ... Trends in neurosciences 39 (11), 750-762, 2016 | 187 | 2016 |
| AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a … CW Ip, LC Klaus, AA Karikari, NP Visanji, JM Brotchie, AE Lang, ... Acta neuropathologica communications 5, 1-12, 2017 | 178 | 2017 |
| Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic … JB Koprich, TH Johnston, MG Reyes, X Sun, JM Brotchie Molecular neurodegeneration 5, 1-12, 2010 | 175 | 2010 |
| Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV α-synuclein rat model of Parkinson’s disease Q He, JB Koprich, Y Wang, W Yu, B Xiao, JM Brotchie, J Wang Molecular neurobiology 53, 2258-2268, 2016 | 153 | 2016 |
| The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration M Deleidi, PJ Hallett, JB Koprich, CY Chung, O Isacson Journal of Neuroscience 30 (48), 16091-16101, 2010 | 134 | 2010 |
| Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein JB Koprich, TH Johnston, P Huot, MG Reyes, M Espinosa, JM Brotchie PloS one 6 (3), e17698, 2011 | 123 | 2011 |
| Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein C McKinnon, ML De Snoo, E Gondard, C Neudorfer, H Chau, SG Ngana, ... Acta Neuropathologica Communications 8 (1), 17, 2020 | 122 | 2020 |
| Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1ΔE9 transgenic mice SE Perez, O Lazarov, JB Koprich, EY Chen, V Rodriguez-Menendez, ... Journal of Neuroscience 25 (44), 10220-10229, 2005 | 97 | 2005 |
| Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model T Musacchio, M Rebenstorff, F Fluri, JM Brotchie, J Volkmann, JB Koprich, ... Annals of neurology 81 (6), 825-836, 2017 | 92 | 2017 |
| Characterization of 3, 4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA … P Huot, TH Johnston, KD Lewis, JB Koprich, MG Reyes, SH Fox, ... Journal of Neuroscience 31 (19), 7190-7198, 2011 | 86 | 2011 |
| Prenatal 3, 4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of … JB Koprich, EY Chen, NM Kanaan, NG Campbell, JH Kordower, ... Neurotoxicology and Teratology 25 (5), 509-517, 2003 | 80 | 2003 |
| The promise and challenges of developing miRNA-based therapeutics for Parkinson’s disease SS Titze-de-Almeida, C Soto-Sánchez, E Fernandez, JB Koprich, ... Cells 9 (4), 841, 2020 | 74 | 2020 |
| A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia MT Henrich, FF Geibl, B Lee, WH Chiu, JB Koprich, JM Brotchie, ... Acta neuropathologica communications 6, 1-19, 2018 | 73 | 2018 |
| The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's … JB Koprich, SH Fox, TH Johnston, A Goodman, B Le Bourdonnec, ... Movement Disorders 26 (7), 1225-1233, 2011 | 72 | 2011 |
| Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice AA Karikari, RL McFleder, E Ribechini, R Blum, V Bruttel, S Knorr, ... Brain, behavior, and immunity 101, 194-210, 2022 | 70 | 2022 |
| Towards a non-human primate model of alpha-synucleinopathy for development of therapeutics for Parkinson’s disease: optimization of AAV1/2 delivery parameters to drive … JB Koprich, TH Johnston, G Reyes, V Omana, JM Brotchie PLoS One 11 (11), e0167235, 2016 | 70 | 2016 |